Organogenesis Holdings Inc. (ORGO) income statement
ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$0.85+0.04 (+5.13%)
Close on Nov 18, 2026Market cap $109.79MP/E –Yield –
Organogenesis Holdings Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -7.8%
- Net margin
- -18.4%
- Return on equity, FY2025
- 13.2%
Financial strength
- Current ratio
- 3.52
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 80.9%
Valuation
- P/E ratio
- –
- Price to sales
- 0.24
- Price to book
- 0.74
- Dividend yield
- –
See a number that looks wrong?